Introduction to Texas Biomed and SNPRC
T he Texas Biomedical Research Institute (Texas Biomed) is a leading nonprofi t institution dedicated to advancing human health through basic biomedical research. Founded in 1941, it is composed of two research departments, the Department of
ABSTRACT
Humans and nonhuman primates (NHPs) are similar in size, behavior, physiology, biochemistry, structure and function of organs, and complexity of the immune system. Research on NHPs generates complementary data that bridge translational research from small animal models to humans. NHP models of human disease offer unique opportunities to develop stem cell -based therapeutic interventions that directly address relevant and challenging translational aspects of cell transplantation therapy. These include the use of autologous induced pluripotent stem cell -derived cellular products, issues related to the immune response in autologous and allogeneic setting, pros and cons of delivery techniques in a clinical setting, as well as the safety and effi cacy of candidate cell lines. The NHP model allows the assessment of complex physiological, biochemical, behavioral, and imaging end points, with direct relevance to human conditions. At the same time, the value of using primates in scientifi c research must be carefully evaluated and timed due to expense and the necessity for specialized equipment and highly trained personnel. Often it is more effi cient and useful to perform initial proof -of -concept studies for new therapeutics in rodents and / or other species before the pivotal studies in NHPs that may eventually lead to fi rst -in -human trials. In this report, we present how the Southwest National Primate Research Center, one of seven NIH -funded National Primate Research Centers, may help the global community in translating promising technologies to the clinical arena. efforts will produce translational data that can demonstrate therapeutic potential and to identify clinical hurdles that must be overcome. In phase I studies, PD patients with neural grafts have experienced improvement in their quality of life for many years [14, 15] . Thus, the proof of concept has been demonstrated; however, the next challenge is to focus on the development of predictable delivery system and a viable stem cell product that meets strict regulatory requirements to ensure the safety and effi cacy of the treatment and eventually successfully move the product toward commercialization and use as a standardized treatment.
Stroke is another area in which NHP models can provide important information on pathophysiology that complements data generated from rodent models of stroke. The importance of NHP models has been highlighted by the Stroke Therapy Academic Industry Roundtable in a set of guidelines that note the need for NHP models of stroke in the preclinical Given the close phylogenetic, immunologic, anatomic, and physiologic similarities to humans, NHP models of human disease are necessary for understanding basic biological mechanisms and for many translational regenerative medicine applications. At the same time, the value of using primates in scientifi c research must be carefully evaluated and timed due to expense and the necessity for specialized equipment and highly trained personnel.
Often it is more effi cient and useful to perform initial proof -of -concept studies for new therapeutics in rodents and / or other species before the pivotal studies in NHPs that may eventually lead to fi rst -in -human trials.
direct cortico -motorneuronal pathway, which is more developed in humans and NHPs than in rodents. NHP models of stroke with exquisite imaging, pathophysiological, and behavioral characterization already have been described [17 -23] , and recent studies illustrate the utility of such models in preclinical development of therapeutic intervention [24 -26] . The ultimate goal of safety and effi cacy studies in NHP models is to better predict outcomes, address challenges, and increase the likelihood of success in human clinical trials.
Ongoing studies at the SNPRC are working on the directed differentiation of PSCs into skeletal muscle, retinal progenitors, and lens epithelium. Early muscle progenitors isolated by fl uorescence -activated cell sorting (FACS) and able to terminally differentiate into mature muscle cells [27] will be utilized for translational studies in animal models, including NHPs. Although NHP models of muscle disease are not available, an artifi cial injury model will be tested to evaluate functional competence of PSCderived muscle progenitors to repair damaged muscle fi bers. Human PSCs are also differentiated toward lens epithelium [28] or retinal progenitors. The resulting cells purifi ed by FACS are going to be grafted in NHP models of cataract or retinal injury. The high accessibility of the eye and minimal invasive procedure will enable investigators to evaluate, first, integration of cells in the host, and then, using a variety of behavioral tests, the ability of grafted cells to ameliorate or restore vision. Those procedures will expand SNPRC capabilities and will help to establish the NHP model as an elective model for preclinical studies.
The SNPRC also has research ongoing studying the deterioration of the vascular endothelium, a critical condition of vascular disorders. Baboon embryonic stem cells (bESCs) are used for deriving endothelial progenitors to reconstruct experimentally damaged arterial vessels [29] . The investigators are developing technologies to engineer vascular tissue by driving vascular progenitors into
